Trial site
Complejo Hospitalario Universitario De Santiago De Compostela
- 8running trials
- 5closed trials
The trials here
What the 13 trials at this site are about, from their registry records.
- Conditions
- Colorectal cancer2 trials
- Acute myeloid leukaemia1 trial
- Aortic stenosis1 trial
- Asthma1 trial
- Atopic dermatitis (eczema)1 trial
- Atrial fibrillation1 trial
- Coronary artery disease1 trial
- Crohn's disease1 trial
- Heart failure1 trial
- High blood pressure1 trial
- Lung cancer1 trial
- Ulcerative colitis1 trial
- Phase
- Phase 33 trials
- Phase 21 trial
- Status
- Completed3 trials
- Recruiting3 trials
- Active, not recruiting2 trials
- Not yet recruiting2 trials
- Terminated2 trials
- Enrolling by invitation1 trial
- Lead sponsor
- Galaxia Empírica2 trials
- Amgen1 trial
- Apollo Therapeutics Ltd1 trial
- BioNTech SE1 trial
- Complejo Hospitalario Universitario de Santiago1 trial
- and 7 more
Running trials
Not yet recruiting
Clinical trial to assess the efficacy and safety of a vaccine for grass pollen allergy.
Recruiting
A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
Enrolling by invitation
Recruiting
Active, not recruiting
Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)
Recruiting
Recruiting
GlycOxiTOD: Multimodal Vascular and Target-Organ Damage Registry
Active, not recruiting
Personalized Therapy Study - Attain Stability Quad Post-Approval Study
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Asthma1 recruiting
- Atopic dermatitis (eczema)1 recruiting
- Colorectal cancer1 recruiting
- Coronary artery disease1 recruiting
- Crohn's disease1 recruiting
- High blood pressure1 recruiting
- Ulcerative colitis1 recruiting
Closed trials
Completed
Safety Evaluation of Edoxaban in Elderly Patients With Frailty Criteria
Terminated
Terminated
Completed
Completed
FORWARD PRO Study Interventional Post-market Study With the Evolut™ PRO System
Site data: ClinicalTrials.govUpdated 13 Nov 2026